Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine

Dominique Rosillon | Corinne Willame | Fernanda Tavares Da Silva | Adrienne Guignard | Sophie Caterina | Sarah Welby | Frank Struyf

Research and Development, GSK, Wavre, Belgium

Correspondence
D. Rosillon, Research and Development, GSK, Avenue Fleming 20, 1300 Wavre, Belgium.
Email: dominique.x.rosillon@gsk.com

Present address: Janssen Research & Development, Beerse, Belgium

Funding information
GlaxoSmithKline Biologicals S.A. was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals S.A. also funded all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data and agreed with the submission of the publication.

Abstract

**Purpose:** To assess the risk of three autoimmune diseases - autoimmune thyroiditis (AIT), Guillain-Barré syndrome (GBS), and inflammatory bowel disease (IBD) - in females following AS04-HPV-16/18 vaccination.

**Methods:** This meta-analysis included data from 18 randomized controlled trials, one cluster-randomized trial, two large observational retrospective cohort studies, and one case-control study. Following vaccination, a risk window of 2 years was defined for AIT and IBD and 42 days for GBS. Odds ratios (ORs) were estimated using three methods: meta-analysis inverse-variance with continuity correction (primary analysis), pooled estimate, and beta-binomial regression.

**Results:** In all studies apart from the case-control study, 154,398 exposed and 1,504,322 non-exposed subjects were included, among whom there were 141 and 1972 cases of (autoimmune) thyroiditis; 2 and 2 cases of GBS; and 43 and 401 cases of IBD, respectively. In the case-control study, there were 97 cases of AIT and 13 of GBS; matched with 802 and 130 controls, respectively. The primary analysis OR estimates were 1.46 (95% confidence interval [CI] 1.22-1.76), 11.14 (2.00-61.92), and 1.11 (0.75-1.66) for (autoimmune) thyroiditis, GBS, and IBD, respectively.

**Conclusions:** This meta-analysis did not show an increased risk of IBD following vaccination with AS04-HPV-16/18. The 1.5-fold increased risk of (autoimmune) thyroiditis does not allow us to conclude about a causal association. For GBS, the very low number of cases and wide 95% CIs negate any firm conclusion.

**KEYWORDS**
autoimmune thyroiditis, Guillain-Barré syndrome, human papillomavirus vaccine, inflammatory bowel disease, pharmacoepidemiology

Trademark statement: Cervarix is a trademark owned by or licensed to the GSK group of companies. Gardasil and Gardasil 9 are trademarks of Merck and Company, Inc.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Pharmacoepidemiology and Drug Safety* published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Three human papillomavirus (HPV) vaccines are currently available: AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine (Cervarix; GSK); quadrivalent HPV-6/11/16/18 (Gardasil; Merck Sharp & Dohme Limited), and a nonavalent HPV vaccine (Gardasil 9; Merck Sharp & Dohme Limited). All three vaccines contain antigens for the high-risk types HPV-16 and HPV-18. AS04-HPV-16/18 also contains AS04 - an adjuvant system containing 3-O-desacyl-4′-monophosphoryl lipid A (50 μg MPL) adsorbed on aluminium hydroxide (500 μg Al3+) to boost the immune response. The other two HPV vaccines contain amorphous aluminium hydroxyphosphate sulphate adjuvant.

For many years, there have been alleged concerns that vaccines, perhaps, may be linked with autoimmune diseases and, more recently, that immunostimulating adjuvants may cause/trigger autoimmune diseases. During the development of AS04-HPV-16/18, clinical trial data did not indicate an increased risk of autoimmune diseases. As part of its safety monitoring, two pooled analyses of AS04-HPV-16/18 clinical trials were undertaken, examining a wide range of autoimmune events. The second and most comprehensive included 33 339 exposed and 24 241 non-exposed subjects. Neither showed an increased risk of autoimmune diseases following AS04-HPV-16/18 vaccination. However, two post-licensure observational studies identified potential safety signals for autoimmune thyroiditis (AIT) and Guillain-Barré syndrome (GBS) after vaccination with AS04-HPV-16/18; and for GBS and inflammatory bowel disease (IBD) following vaccination with HPV-6/11/16/18.

In order to test these signals, we performed a meta-analysis to estimate the risk of AIT, GBS, and IBD in females following vaccination with AS04-HPV-16/18.

2 | METHODS

2.1 | Study selection

This meta-analysis included data from randomized controlled trials (RCTs) and post-marketing observational studies that were identified in GSK internal repository of studies sponsored and supported by the Company, and information from Regulatory Authorities. In a complementary, systematic literature review searching for all studies published till end 2015. Details of the search strategy, the database consulted and number of references found and selected are described in Data S1. No study additional to those included in the GSK internal repository was found. AS04-HPV-16/18 clinical trials had to be interventional RCTs with a non-HPV vaccine control group in female subjects aged ≥9 years. Extension studies beyond 2 years following first vaccination and ongoing studies on the data lock point date (17 November 2015) were excluded. Post-marketing observational studies that specifically assessed the association between AS04-HPV-16/18 and autoimmune diseases in females were also included.

The following studies were included:

- Eighteen individually RCTs (Data S2) that were pooled.
Clinical definitions of AIT, GBS, and IBD events varied across studies, as detailed in Data S4. Briefly, the clinical studies9-26 and the cluster-randomized trial31,32 used MedDRA terminology; while the two cohort studies29,30,33,34 used International Classification of Diseases, 10th Revision (ICD-10) codes. The complementary analysis of (autoimmune) thyroiditis in the French cohort study defined cases by the use of thyroid disorder drugs combined with either routine thyroid function tests and complementary examination of the thyroid, or hospital stays with ICD-10 codes for thyroiditis, or a “new full coverage for thyroiditis as a long-term illness”.33 The UK cohort study30 also used “Read codes” classification and only included cases that were confirmed by a medical review of the charts. The case-control study35,36 identified cases of autoimmune disorders through a network of specialist centres at university and general hospitals across France.

In the French cohort study,29,33,34 autoimmune and non-autoimmune thyroiditis cases were included as these were not differentiated in the reports. Therefore, a sensitivity analysis of AIT was performed excluding the French cohort study data.33

### 2.4 | Risk periods

The post-vaccination risk periods were determined based on the onset of the disease (acute or insidious) and possible or known pathologic mechanisms.38 Irrespective of the underlying mechanisms, it can be assumed that the development of autoimmunity generally requires several weeks, if a causal association between the event and vaccination existed, which is similar to the classical timeframe of several weeks suggested for the onset of post-infectious autoimmune phenomena.38,39

As the clinical courses of AIT and IBD are generally insidious, 2 years between vaccination and disease onset was selected. For trials with longer follow-up periods, only cases that occurred during the 2 years following first vaccination were included. For the French cohort study,29,33,34 only the total numbers of events and the mean follow-up periods were known. Further, events were reported in exposed subjects and non-exposed subjects, which included a combination of non-vaccinated subjects plus the pre-exposure periods of subjects who were subsequently vaccinated with AS04-HPV-16/18 or HPV-6/11/16/18. Events were therefore estimated as detailed in Data S5.

For GBS, a shorter risk period (42 days following each vaccination) was considered for the main analysis, based on its anticipated acute onset. This period is also recommended by the Brighton Collaboration GBS Working Group40 based on epidemiological data collected after swine flu vaccination during 1976-1977.41,42 For the French cohort study,29,34 the time-to-onset of the two GBS cases reported among exposed individuals was unknown. We conservatively assumed that these occurred during the 42 days following a vaccination dose and estimated non-exposed cases as detailed in Data S5. A sensitivity analysis for GBS included cases that occurred during the 2 years following first vaccination.

### 2.5 | Statistical methods

To harmonize results across studies, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from the numbers of cases and total numbers of subjects for the combined clinical studies (Data S2); the cluster-randomized trial31,32; each of the two cohort studies (UK30 and French29,33,34); and the case-control study.35,36 Meta-analysis of rare events is challenging due to the inclusion of studies with no event in one or both arms (“single-zero” and “double-zero,” respectively).43,44 Therefore, three meta-analysis methods to estimate ORs were used.

In the inverse-variance method (primary analysis), a continuity correction (please see Data S6) was applied to all studies to overcome the single- and double-zero issue. This method was chosen as the primary analysis because all studies could be included and study heterogeneity could be estimated. In the pooled estimate method, data from all the studies except the case-control study35,36 were pooled and an overall estimate was computed.45 The beta-binomial regression method can include single- and double-zero studies without using continuity correction. Two different beta-binomial models were analyzed, including, or not, the case-control study.35,36 All statistical analyses were performed using SAS and StatXact-8.1 procedure for SAS.

### 3 | RESULTS

#### 3.1 | Study population

In 21 studies (all apart from the case-control study25,26), 154 398 exposed (9.3%) and 1 504 322 non-exposed (90.7%) subjects were included (Table 1). This imbalance was due to the much larger non-exposed cohort in the French cohort study.29,34 The population sizes varied widely between studies, with 19 studies accounting for 3.8% of subjects, and the two cohort studies adding 7.8%29,30 and 88.4%.29,34 Exposed subjects were older than non-exposed subjects (mean age 16.1 vs 13.7 years) due to the imbalance in the French cohort study.29,34

In the aggregated data study (case-control study),35,36 97 subjects with definite AIT were matched with 802 healthy controls. Only six subjects were exposed to AS04-HPV-16/18 vaccine, none of whom developed AIT (ie, all six were in the control group). Thirteen subjects with definite GBS were matched with 130 controls. None of these were vaccinated with AS04-HPV-16/18 during the preceding 42 days. IBD was not assessed in this study.

#### 3.2 | AIT

There were an estimated 140.6 cases of (autoimmune) thyroiditis among 152 225 exposed subjects (92/100 000) and 1971.5 cases among 1 453 729 non-exposed subjects (136/100 000). The OR using the inverse-variance method with continuity correction (primary method) was 1.46 (95% CI 1.22-1.76), the beta-binomial regression
method without the case-control study gave a similar OR estimate but had a broader CI, and the pooled OR estimate was 0.68 (95% CI 0.57-0.81) (Figure 1).

Results using the original analysis of the French cohort study due to the standardization of the follow-up time to 2 years; and for the case-control study due to the continuity correction factor due to the "single-zero" cases in the exposed arm. AIT, autoimmune thyroiditis; AS04-HPV-16/18, AS04-adjuvanted human papillomavirus-16/18 vaccine; CI, confidence interval; OR, odds ratio; RCTs, randomized controlled trials; UK, United Kingdom. *The case-control study was not included in the pooled estimate.

FIGURE 1 Risk of (autoimmune) thyroiditis during 2 years following the first dose of AS04-HPV-16/18. There were partial events for the French cohort study due to the standardization of the follow-up time to 2 years; and for the case-control study due to the continuity correction factor due to the "single-zero" cases in the exposed arm. AIT, autoimmune thyroiditis; AS04-HPV-16/18, AS04-adjuvanted human papillomavirus-16/18 vaccine; CI, confidence interval; OR, odds ratio; RCTs, randomized controlled trials; UK, United Kingdom. *The case-control study was not included in the pooled estimate.

3.3 | GBS

The only GBS cases were from the French cohort study, in which there were two cases of GBS in exposed subjects and 21 cases among non-exposed subjects (estimated to equate to 1.76 cases during the equivalent follow-up period in the non-vaccinated cohort).

The primary method OR was 11.14 (95% CI 2.00-61.92; Figure 2). The pooled estimate results were similar, while the beta-
Binomial regression method gave a lower estimate, although this was questionable because the low number of cases did not allow model convergence criteria to be met. When the risk period was increased to 2 years, the primary method OR was 3.83 (95% CI 1.08-13.57), with lower OR estimates using the other methods (Data S8).

### 3.4 | IBD

There were 42.5 cases of IBD among 154,398 exposed subjects (28/100,000) and 401.4 cases among 1,504,322 non-exposed subjects (27/100,000). The primary method OR was 1.11 (95% CI 0.75-1.66); the other methods gave similar estimates (Figure 3).

### 4 | DISCUSSION

This meta-analysis of AS04-HPV-16/18 studies was performed to study three autoimmune diseases (AIT, GBS, and IBD) that had been identified as safety signals in observational studies of AS04-HPV-16/18 or HPV-6/11/16/18 vaccines. The analysis included 18 RCTs, one cluster-randomized trial, two large observational, retrospective cohort studies, and one case-control study, which combined included approximately 150,000 exposed and 1,500,000 non-exposed subjects. Risk among females was assessed during pre-defined risk periods (2 years for AIT and IBD; 42 days for GBS).

The AIT primary analysis showed a slightly increased risk (OR = 1.46) of (autoimmune) thyroiditis following AS04-HPV-16/18 vaccination. This is likely a slight overestimation of risk given that this was heavily influenced by the large French cohort study, for which we calculated an OR of 1.41 (95% CI 1.17-1.72) based on their crude data, but for which they reported an age-adjusted hazard ratio (HR) for (autoimmune) thyroiditis of 1.19 (95% CI 0.93-1.51). Despite this difference, both estimates are similar and <1.5.

The other analysis methods showed ambiguous results for AIT due to differences in their weighting of data from different studies. The binomial model estimate was similar to that from the primary analysis, but the pooled analysis estimate provided an OR of 0.68. This simple pooled estimate is biased because there was a much higher incidence of (autoimmune) thyroiditis in the French cohort study than in the other studies (exposed: 203 vs 23-56/100,000; non-exposed: 144 vs 6-37/100,000) and the non-exposed cohort was much larger than the exposed cohort (1,360,003 vs 53,372). These differences in incidence probably reflect to differences in case definitions (Data S4), as the French cohort study included all thyroiditis cases (ie, autoimmune and non-autoimmune), whereas the other studies specifically included AIT, and the French cohort study included inpatient and outpatient cases. The French cohort study therefore overcontributed to the incidence in the non-exposed cohort, resulting in a lower OR estimate.
in a biased OR < 1. In addition to these limitations, most of the Hill’s causal criteria for observational studies such consistency, specificity, coherence, analogy, experimental evidence, etc. were not met. Similarly, the causality criteria on vaccine adverse events adopted by the Institute of Medicine were also not encountered: the weight of epidemiological evidence is limited as well as and a plausible biological mechanism has not been identified. Therefore, there is insufficient evidence to conclude a causal relationship between AS04-HPV-16/18 and AIT. Similar findings and conclusions have been published for HPV-6/11/16/18.

The GBS results were driven by two cases among exposed individuals in the French cohort study, which were conservatively assumed to have occurred within 42 days following vaccination. The French cohort study reported an adjusted HR of 8.14 (95% CI 1.70-38.92), while our OR estimate was much higher (28.84 [95% CI 3.91-218.62]), partly due to the different methodology and lack of age adjustment, but mainly because we conservatively assumed that both GBS cases occurred within 42 days of vaccination. In our sensitivity analysis, when cases of GBS to 2 years were considered, our OR was much more in line with that reported in the French cohort study (3.83 [95% CI 1.08-13.57]). This was the only study that reported any GBS cases among AS04-HPV-16/18 vaccinated subjects. Given the low number of GBS cases (2/154398 exposed subjects) and the large CI, the risk of GBS following AS04-HPV-16/18 vaccination cannot be reliably quantified. Of note, a recent English study found no evidence of an increased risk of GBS during 3 months following vaccination (vs other periods) with AS04-HPV-16/18 (relative incidence 0.84; 95% CI 0.30-2.34). Further, no increased risk of GBS following vaccination with HPV-6/11/16/18 has been reported in other studies.

The IBD primary analysis did not show an increased risk following AS04-HPV-16/18 vaccination. This is in line with previous AS04-HPV-16/18 pooled analyses. In the current analysis, for every 100,000 subjects vaccinated vs not, IBD was reported for 28 vs 27. This is aligned with results from a 1-year database cohort study carried out prior to the introduction of HPV vaccines (2005), in which 35 outpatient cases per 100,000 female adolescents were reported for presumed autoimmune “ulcerative colitis.” These similarities support the lack of an increased risk of IBD with AS04-HPV-16/18.

Our results are also supported by a recent systematic review and meta-analysis that examined the risk of various autoimmune disorders after vaccination with any HPV vaccine. They reported non-significant ORs between HPV vaccination and combined autoimmune disorders (1.00 [95% CI 0.95-1.06]), AIT (1.02 [0.91-1.14]), GBS (1.28 [0.65-2.52]), and IBD (1.05 [0.97-1.14]). They also examined various other autoimmune disorders and none had a significant association with HPV vaccination apart from a small increased risk of Hashimoto’s thyroiditis (1.22 [1.09-1.36]).

### FIGURE 3

Risk of IBD during 2 years following the first dose of AS04-HPV-16/18. There are partial events for the French cohort study due to the standardization of the follow-up time to 2 years. AS04-HPV-16/18, AS04-adjuvanted human papillomavirus-16/18 vaccine; CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio; RCTs, randomized controlled trials; UK, United Kingdom.
events in one or both arms.\textsuperscript{43,44} The strength of the meta-analytical methods employed is that they allowed inclusion of all available information, regardless of the source or study design, resulting in a large sample size. However, as no quality of evidence assessment was performed prior to the meta-analysis, the only factor contributing to the weight of each study was linked to the size of the population. The results of this meta-analysis were, therefore, driven by the two largest studies,\textsuperscript{29,30,34} which together contributed 78.1% of exposed and 98.1% of non-exposed subjects.

There was also heterogeneity between studies, in terms of study design, coding of medical events (Data S4), case ascertainment methods, outcome collection methods, outcome onset identification (eg, diagnosis date vs date of first clinical signs/symptoms), and subject ages. Despite these differences, heterogeneity - as assessed by the $I^2$ index (see Figures) - appeared to be very low, although the CIs were very broad, so the apparent lack of heterogeneity should be interpreted with caution.

Regarding study design, the AS04-HPV-16/18 exposed and non-exposed arms of the RCTs should have been balanced by randomization, but there could have been multiple unknown confounders between arms in the observational studies, which it is impossible to adjust for. Also, subjects in both arms could have received additional vaccines, with or without adjuvants, further complicating interpretation of the results. Another difference between the RCTs and observational cohort studies is the level of medical surveillance. In the RCTs, vaccinated and control subjects were followed up according to protocol-defined scheduled visits. However, in the two observational cohort studies,\textsuperscript{29,30,33,34} cases of autoimmune diseases were diagnosed in routine medical practice. By definition, the risk period in vaccinated subjects started at the time of the first dose, so vaccinated subjects in observational studies would have contact with a healthcare professional for subsequent dose(s), increasing the likelihood that an autoimmune disease would be diagnosed in the exposed vs non-exposed subjects. Such an “unmasking” effect has been reported in a post-licensure study of autoimmune diseases following HPV-6/11/16/18 vaccination.\textsuperscript{56}

The case-control study\textsuperscript{35,36} had a very different design to the other studies, namely it identified girls with autoimmune diseases and matched them with age- and place of residence-matched controls. HPV vaccination status among these two groups was then ascertained. This study could capture events among a large cohort, but the number of subjects included in the study was quite small. It should also be noted that around 1% and 14% of the “non-exposed” girls in the GBS and AIT analyses, respectively, received HPV-6/11/16/18.

Case definitions and ascertainment methods varied between studies. In the RCTs, all cases were fully medically validated, whereas in the French cohort study,\textsuperscript{29,33,34} there was no validation, and in the UK cohort study,\textsuperscript{30} there was an intermediate level of validation based on algorithms and patient medical data review. Exposure status validity also varied among studies. Exposure accuracy is close to 100% in clinical trials, but could be uncertain in observational studies. Exposure accuracy was improved in the UK cohort study\textsuperscript{30} by including a historical (pre-vaccination implementation) non-exposed cohort. However, in the French cohort study,\textsuperscript{29,33,34} concomitant exposed and non-exposed cohorts could have reduced exposure accuracy.

Unfortunately, individual subject data (including time-to-event data) for the case-control study\textsuperscript{35,36} and the French cohort study\textsuperscript{29,33,34} were not available, which precluded adjustment for covariates. We had to calculate ORs rather than use their published HRs in order to have a common parameter for all studies. Also in the French cohort study,\textsuperscript{29,33,34} no distinction was made between AIT and non-autoimmune thyroiditis, limiting the clinical evaluation and interpretation of the findings regarding AIT. For the 42-day GBS analysis, the number of cases in the French cohort study control group had to be estimated from the overall data, assuming a constant incidence rate. It was assumed that early termination did not depend on exposure and, while this was a reasonable assumption for the other studies (even though subjects could withdraw at any time), this was not the case for the French cohort study. The switch from non-exposed to exposed status in the French cohort study\textsuperscript{29,33,34} also resulted in a higher mean age for the exposed cohort.

Ideally, disease onset would be from the date of first symptoms, but this is not necessarily known, especially in retrospective database studies. Using diagnosis dates, some autoimmune cases that were diagnosed after vaccination may have had their first symptoms prior to vaccination. Conversely, some cases with first symptoms within 2 years or 42 days following vaccination might have been diagnosed after these windows and therefore not have been included.

Overall, our analysis illustrates that a meta-analysis can be powerful tool, but its strength is related to the quality of the input data.

5 CONCLUSIONS

This meta-analysis - including approximately 150 000 AS04-HPV-16/18-exposed and 1 500 000 non-exposed subjects - did not indicate an increased risk of IBD. The results of the analysis showed a 1.5-fold increased risk of (autoimmune) thyroiditis, but based on existing epidemiological and mechanistic evidence, there is insufficient evidence to conclude a causal association with vaccination. No conclusion regarding the risk of GBS can be drawn as they were driven by two cases among exposed individuals, the times-to-onset of which were unknown. Although the GBS OR estimates were high, the number of cases was low and the 95% CIs were wide.

Considering the current results and ongoing surveillance of AS04-HPV-16/18 vaccination including other available post-marketing data and pooled analyses of clinical trial data,\textsuperscript{27,28} there is no evidence to confirm the hypothesis of an association between these autoimmune diseases and AS04-HPV-16/18 vaccination.

Given the overall safety data and the demonstrated high and sustained efficacy of AS04-HPV-16/18 against HPV-16/18 infection and cervical lesions,\textsuperscript{9,11,14,21,57-59} and the potential impact of high-risk HPV infection (ie, cervical lesions and cervical cancer), we conclude that the results of the study does not modify the safety and benefit profile of the vaccine.
ETHICS STATEMENT
The authors state that no ethical approval was needed.

ACKNOWLEDGEMENTS
The Authors would like to thank Pallas health research and consultancy B.V. for the conduct of the systematic literature review. The authors would also like to thank Bernard Hoet and Dorotha Borys for their critical review of the manuscript and writing contribution. Business & Decision Life Sciences platform provided editorial assistance and manuscript coordination, on behalf of GSK. Jonathan Ghesquiere coordinated manuscript development and editorial support. Jenny Lloyd (Compass Medical Communications Ltd., on behalf of GSK) provided medical writing services.

CONFLICT OF INTEREST
A.G., C.W., D.R., F.T.D.S., S.C., S.W. are employees of the GSK group of companies. A.G., D.R., F.S., F.T.D.S., S.W. hold shares in the GSK group of companies as part of their employee remuneration. F.S. was an employee of the GSK group of companies at the time the study was performed and is currently an employee of Janssen, Pharmaceutical Companies of Johnson & Johnson. F.S. owns shares in the GSK group of companies.

AUTHOR CONTRIBUTIONS
D.R., C.W. and F.T.D.S. were involved in the design of the study, collection of the data, and interpretation of the results. D.R. and S.C. were involved in the statistical analysis. A.G. and S.C. were involved in the interpretation of the results. F.S. was involved in the design of the study and interpretation of the results.

ORCID
Dominique Rosillon https://orcid.org/0000-0001-7230-1978
Corinne Willame https://orcid.org/0000-0002-6310-6019

REFERENCES
1. European Medicines Agency. Cervarix. https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix. Accessed January 10, 2019.
2. European Medicines Agency. Gardasil. https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil. Accessed January 10, 2019.
3. European Medicines Agency. Gardasil 9. https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil9. Accessed January 10, 2019.
4. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723-739.
5. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1-16.
6. Baker B, Eco Guimaraes L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf. 2015;14:1387-1394.
7. Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.
8. Vera-Lastre O, Medina G, Cruz-Dominguez Mdel P, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol. 2013;9:361-373.
9. Harper DM, Franco EL, Wheeler C, et al; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
10. Harper DM, Franco EL, Wheeler CM, et al; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
11. Paavonen J, Naud P, Salmeron J, et al; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precursor caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
12. Herrero R, Wacholder S, Rodriguez AC, et al; Costa Rica Vaccine Trial Group. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1:408-419.
13. Medina DM, Valencia A, de Velasquez A, et al; HPV-013 Study Group. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46:414-421.
14. Skinner SR, Szarewski A, Romanowski B, et al; VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213-2227.
15. Denny L, Hendrickx B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31:5745-5753.
16. Sow PS, Watson-Jones D, Kiviat N, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. 2013;207:1753-1763.
17. Leroux-Roels G, Haelterman E, Maes C, et al. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Clin Vaccine Immunol. 2011;18:1510-1518.
18. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomised study in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. 2015;207:1753-1763.
19. Schmeink CE, Bekkers RL, Joseffson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine. 2011;29:9276-9283.
20. Bhatta N, Suri V, Basu P, et al; Indian HPV Vaccine Study Group. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res. 2010;36:123-132.
21. Konno R, Tamura S, Doebbeliere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer. 2010;20:847-855.
22. Kim YI, Kim KT, Kim JH, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci. 2010;25:1197-1204.
23. Ngn HY, Cheung AN, Tam KF, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J. 2010;16:171-179.
24. Lim BK, Ng KY, Omar J, et al. Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine in Malaysian women aged 18-35 years: a randomized controlled trial. Med J Malaysia. 2014;69:2-8.
25. Zhu F, Li J, Hu Y, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. *Hum Vaccin Immunother*. 2014;10:1795-1806.

26. Kim SC, Song YS, Kim YT, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. *J Gynecol Oncol*. 2011;22:67-75.

27. Verstreuten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. *Vaccine*. 2008;26:6630-6638.

28. Angelo MG, David MP, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. *Pharmacoepidemiol Drug Saf*. 2014;23:466-479.

29. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Vaccination contre les infections à HPV et risque de maladies auto-immunes : une étude Cnamts/ANSM rassurante - Point d'information. [Accessed 2015-12-28].

30. Willame C, Rosillon D, Zima J, et al. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. *Hum Vaccin Immunother*. 2016;12:2862-2871.

31. Lehtinen M, Apter D, Baussano I, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015;33:1284-1290.

32. GSK. An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix in the United Kingdom. Study number 116239 (EPI-HPV-040 VS UK). [Accessed 2015-10-25].

33. Collin C, Miranda S, Zureik M, Dray-Spira R. HPV vaccines and the risk of thyroiditis in girls. Complementary analyses of the French cohort based on data from SNIIRAM of the ANSM in collaboration with CNAMTS. 2018.

34. Miranda S, Chaignot C, Collin C, Dray-Spira R, Weill A, Zureik M. Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine. 2017;35:4761-4768.

35. Grimaldi-Bensouda L, Rossignol M, Kone-Paut I, et al; PGRx-AID Study Group. Risk of autoimmune diseases and human papillomavirus (HPV) vaccines: six years of case-referent surveillance. *J Autoimmun*. 2017;79:84-90.

36. Grimaldi-Bensouda L, Aubrun E, Abenhaim L. Analysis of Cervarix® & Autoimmune Disorders Using the PGRx Information System. Data on File; 2015.

37. GSK. Meta-analysis of the risk of autoimmune thyroiditis diseases, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with Cervarix. [Accessed 2017-01-25].

38. Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. *Vaccine*. 2013;31:1870-1876.

39. Allos BM. Association between campylobacter infection and Guillain-Barré syndrome. *J Infect Dis*. 1997;176(Suppl 2):S125-S128.

40. Sejvar JJ, Kohl KS, Gidudu J, et al; Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2011;29:599-612.

41. Langmuir AD. Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976–77: preliminary communication. *J R Soc Med*. 1979;72:660-669.

42. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. *Am J Epidemiol*. 1979;110:105-123.

43. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med*. 2004;23:1351-1375.

44. Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med*. 2007;26:53-77.

45. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.

46. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. *Nature*. 2019;567:305-307.

47. XXX 2019. It's time to talk about ditching statistical significance. *Nature*. 2019;567:283 doi: 10.1038/d41586-019-00874-8.

48. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58:295-300.

49. Committee to Review Adverse Effects of Vaccines; Institute of Medicine, In Stratton K, Ford A, Rusch E, Wright Clayton E (Eds.) Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: National Academies Press (US); 2011.

50. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity*. 2010;33:492-503.

51. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *J Intern Med*. 2012;271:193-203.

52. Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. *Vaccine*. 2017;35:1729-1732.

53. Grimaldi-Bensouda L, Guillermot D, Godeau B, et al; PGRx-AID Study Group. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. *J Intern Med*. 2014;275:398-408.

54. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. *Pediatr Infect Dis J*. 2007;26:979-984.

55. Jiang HY, Shi YD, Zhang X, et al. Human papillomavirus vaccination and the risk of autoimmune disorders: a systematic review and meta-analysis. *Vaccine*. 2019;37:3031-3039.

56. Jacobsen SJ, Sy LS, Ackerson BK, et al. An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. *Vaccine*. 2012;30:4585-4587.

57. Szarewski A, Poppe WA, Skinner SR, et al; HPV PATRICIA Study Group. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. *Int J Cancer*. 2012;131:106-116.

58. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. *Vaccine*. 2010;28:6247-6255.

59. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. *Hum Vaccin Immunother*. 2012;8:390-397.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.